Altimmune to Present Clinical Data from Pemvidutide at Upcoming EASL International Liver Congress™ 2024
May 29 2024 - 7:30AM
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical
company, today announced that new data on the anti-inflammatory and
anti-fibrotic properties of pemvidutide in subjects with metabolic
dysfunction-associated steatotic liver disease (MASLD) will be
presented at the EASL International Liver Congress™ 2024 in Milan,
Italy. Pemvidutide is a novel, investigational, peptide-based
GLP-1/glucagon dual receptor agonist in development for the
treatment of obesity and metabolic dysfunction-associated
steatohepatitis (MASH).
Details for the presentations are as
follows:
Title: |
Pemvidutide, a glucagon-like peptide 1/glucagon dual receptor
agonist, improves metabolic dysfunction-associated steatohepatitis
activity and fibrosis in a clinical quantitative systems
pharmacology model(abstract #2881) |
Presenter: |
Sarah Browne, M.D., Vice President, Clinical Development,
Altimmune |
Date/Time: |
Wednesday, June 5, 2024, at 8:30 am CEST |
Title: |
Plasma lipidomic profiling of subjects with overweight or obesity
following treatment with the glucagon-like peptide 1/glucagon dual
receptor agonist pemvidutide: an investigation of lipid signatures
associated with metabolic dysfunction-associated
steatohepatitis(abstract #2985) |
Presenter: |
Scot Roberts, Ph.D., Chief Scientific Officer, Altimmune |
Date/Time: |
Wednesday, June 5, 2024, at 8:30 am CEST |
Title: |
Pemvidutide treatment is associated with improvement in noninvasive
tests indicating greater likelihood of histologic response in
subjects with metabolic dysfunction-associated steatotic liver
disease: a 24-week, randomized, double-blind, placebo-controlled
trial(abstract #3002) |
Presenter: |
Shaheen Tomah, M.D., Associate Director, Clinical Development,
Altimmune |
Date/Time: |
Wednesday, June 5, 2024, at 8:30 am CEST |
These posters will be displayed during the four
days of the congress and a copy will be accessible on the Events
section of the Altimmune website.
About PemvidutidePemvidutide is a novel,
investigational, peptide-based GLP-1/glucagon dual receptor agonist
in development for the treatment of obesity and MASH. Activation of
the GLP-1 and glucagon receptors is believed to mimic the
complementary effects of diet and exercise on weight loss, with
GLP-1 suppressing appetite and glucagon increasing energy
expenditure. Glucagon is also recognized as having direct effects
on hepatic fat metabolism, which is believed to lead to rapid
reductions in levels of liver fat and serum lipids. In clinical
trials to-date, once-weekly pemvidutide has demonstrated compelling
weight loss, robust reductions in triglycerides, LDL cholesterol,
liver fat content and blood pressure. The U.S. FDA has granted Fast
Track designation to pemvidutide for the treatment of MASH.
Pemvidutide recently completed the MOMENTUM Phase 2 obesity trial
and is being studied in the ongoing IMPACT Phase 2b MASH trial.
About AltimmuneAltimmune is a clinical-stage
biopharmaceutical company focused on developing innovative
next-generation peptide-based therapeutics. The Company is
developing pemvidutide, a GLP-1/glucagon dual receptor agonist for
the treatment of obesity and MASH. For more information, please
visit www.altimmune.com.
Follow @Altimmune, Inc. on
LinkedInFollow @AltimmuneInc on
Twitter
Company Contact:Richard
Eisenstadt Chief
Financial Officer
Phone:
240-654-1450 ir@altimmune.com
Investor Contacts:Lee RothBurns McClellanPhone:
646-382-3403lroth@burnsmc.com Julia WeilmanBurns McClellanPhone:
646-732-4443jweilman@burnsmc.com
Media Contact:Danielle CanteyInizio Evoke,
BiotechPhone: 619-826-4657Danielle.cantey@inizioevoke.com
Altimmune (NASDAQ:ALT)
Historical Stock Chart
From Sep 2024 to Oct 2024
Altimmune (NASDAQ:ALT)
Historical Stock Chart
From Oct 2023 to Oct 2024